Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 2c, provides guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
EPS Growth %: -60.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -60.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $50.04 million versus the consensus estimate of $61.02 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $222.9 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts Shake Shack (SHAK) at Outperform
- UBS Downgrades Lai Yih Footwear Co Ltd (6890:TT) to Neutral
- DBS Group Downgrades RoboSense Technology (2498:HK) to Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
